Dengue haemorrhagic fever or dengue shock syndrome in children.

BMJ clinical evidence Pub Date : 2015-04-10

Marissa M Alejandria

{"title":"Dengue haemorrhagic fever or dengue shock syndrome in children.","authors":"Marissa M Alejandria","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: Dengue haemorrhagic fever and dengue shock syndrome are major causes of hospital admission and mortality in children.Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of supportive treatments for dengue haemorrhagic fever or dengue shock syndrome in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2014 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).Results: We found nine studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding blood component transfusion to standard intravenous fluids; adding corticosteroids or intravenous immunoglobulin to standard intravenous fluids; and crystalloids versus colloids.","PeriodicalId":72432,"journal":{"name":"BMJ clinical evidence","volume":"2015 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392842/pdf/2015-0917.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ clinical evidence","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Dengue haemorrhagic fever and dengue shock syndrome are major causes of hospital admission and mortality in children.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of supportive treatments for dengue haemorrhagic fever or dengue shock syndrome in children? We searched: Medline, Embase, The Cochrane Library, and other important databases up to March 2014 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found nine studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding blood component transfusion to standard intravenous fluids; adding corticosteroids or intravenous immunoglobulin to standard intravenous fluids; and crystalloids versus colloids.

本刊更多论文

儿童登革出血热或登革休克综合症。

简介：登革出血热和登革休克综合征是儿童入院和死亡的主要原因：登革出血热和登革休克综合征是儿童入院和死亡的主要原因：我们进行了一项系统回顾，旨在回答以下临床问题：儿童登革出血热或登革休克综合征的支持治疗效果如何？我们检索了截至 2014 年 3 月的 Medline、Embase、Cochrane 图书馆和其他重要数据库（临床证据综述会定期更新，请在我们的网站上查看本综述的最新版本）。我们还纳入了美国食品药品管理局 (FDA) 和英国药品与保健品监管局 (MHRA) 等相关机构发布的危害警报：我们发现有九项研究符合纳入标准。我们对干预措施的证据质量进行了 GRADE 评估：在本系统综述中，我们介绍了以下干预措施的有效性和安全性：在标准静脉输液中加入血液成分输注；在标准静脉输液中加入皮质类固醇或静脉注射免疫球蛋白；晶体液与胶体液。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ clinical evidence

自引率

0.00%

发文量